Jing Wang is a Principal Scientist at Genentech, where she leverages her extensive expertise in small molecule drug discovery and development to drive innovative research initiatives. With a comprehensive understanding of FDA and international regulations, Jing plays a pivotal role in ensuring that regulatory submissions...
Jing Wang is a Principal Scientist at Genentech, where she leverages her extensive expertise in small molecule drug discovery and development to drive innovative research initiatives. With a comprehensive understanding of FDA and international regulations, Jing plays a pivotal role in ensuring that regulatory submissions meet the highest standards of compliance. Her certification in biotechnology project management further enhances her ability to navigate complex project landscapes, making her an invaluable asset to cross-functional research teams.
In her current role, Jing serves as a DMPK (Drug Metabolism and Pharmacokinetics) project representative, where she collaborates closely with colleagues from various disciplines, including biochemistry, high throughput screening, and in vivo studies. Her contributions are critical in advancing projects from early discovery phases through to development, particularly in the context of cancer therapeutics. Jing’s expertise in ADME (Absorption, Distribution, Metabolism, and Excretion) allows her to provide insights that optimize drug candidates for efficacy and safety.
Jing’s work is characterized by her commitment to validation processes that ensure the reliability of experimental data. By serving as a liaison between different research teams, she fosters communication and collaboration, which are essential for the successful translation of scientific discoveries into viable therapeutic options. Her passion for life sciences and dedication to advancing drug discovery not only exemplify her professional insights but also underscore her role as a leader in the field, driving forward the mission of Genentech to develop groundbreaking treatments for patients in need.
